EGFR Signaling Networks in Cancer Therapy

  • John D. Haley
  • William John Gullick

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages 1-11
  2. EGFR Signaling Networks

    1. Front Matter
      Pages 1-1
    2. Antony W. Burgess, Thomas P.J Garrett
      Pages 2-13
    3. Priya Koppikar, Jennifer Rubin Grandis
      Pages 69-83
    4. Marie Wislez, Jonathan M. Kurie
      Pages 84-90
    5. Jessica E. Pritchard, Allison B. Jablonski, Sarah J. Parsons
      Pages 112-130
    6. Julie Gavard, J. Silvio Gutkind
      Pages 131-146
    7. Kermit L. Carraway III, Lily Yen, Ellen Ingalla, Colleen Sweeney
      Pages 161-178
    8. Hong-Jun Liao, Graham Carpenter
      Pages 179-189
    9. Blagoy Blagoev, Irina Kratchmarova, Jesper V. Olsen, Matthias Mann
      Pages 190-198
    10. Colin G. Johnson, Emmet McIntyre, William Gullick
      Pages 199-208
  3. EGFR in Tumorigenesis and EGFR Tyrosine Kinase Inhibitors in Cancer Therapy

    1. Front Matter
      Pages 209-209
    2. Nicola Normanno, Caterina Bianco, Antonella De Luca, Luigi Strizzi, Marianna Gallo, Mario Mancino et al.
      Pages 210-223
    3. Haley L. Bennett, Tilman Brummer, Paul Timpson, Kate I. Patterson, Roger J. Daly
      Pages 224-244
    4. Carol Box, Joanna Peak, Susanne Rogers, Suzanne Eccles
      Pages 245-264
    5. Carol J. Wikstrand, Darell D. Bigner
      Pages 265-280
    6. Andrew J. Dannenberg, Kotha Subbaramaiah
      Pages 325-339
    7. Stuart Thomson, John D. Haley, Robert Yauch
      Pages 340-355
    8. Elizabeth Buck, Alexandra Eyzaguirre, Kenneth K. Iwata
      Pages 356-369
  4. Back Matter
    Pages 1-11

About this book


The epidermal growth factor (EGF) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGFR therapies. Edited by John Haley and William J. Gullick, EGFR Signaling Networks in Cancer Therapy, is separated into two sections. The first of which probes the molecular pathways and the intersection of signaling networks which are frequently deregulated in human cancers, with a view to describing EGF receptor in a tumor tissue specific context. Meanwhile, the second section illustrates the many ways in which EGF receptor contribute to abnormal survival and migration signaling in cancer cells and to epithelial to mesenchymal transition and metastasis. The book also describes the mitogenic, survival, adhesive and migratory pathways within a framework of interacting subsystems that contribute to the activity and physiological regulation of the receptor in normal and neoplastic tissues. Even though there is still much to learn, this volume explores this fascinating system with compelling information.


EGFR STAT 3 Signaling networks angiogenesis enzymes glioblastoma heterodimerization inhibitors kinase domain solid tumors tumorigenesis

Editors and affiliations

  • John D. Haley
    • 1
  • William John Gullick
    • 2
  1. 1.OSI Pharmaceuticals, Inc.FarmingdaleU.S.A.
  2. 2.Dept. BiosciencesUniversity of KentCanterbury, KentUnited Kingdom

Bibliographic information

  • DOI
  • Copyright Information Humana Press, a part of Springer Science+Business Media, LLC 2008
  • Publisher Name Humana Press
  • eBook Packages Medicine Medicine (R0)
  • Print ISBN 978-1-58829-948-2
  • Online ISBN 978-1-59745-356-1
  • Buy this book on publisher's site